Search results
Results from the WOW.Com Content Network
In general, overall survival rates after 5, 10, and 15 years of treatment have been 95%, 85%, and 78% respectively. While the response to these therapeutic regimens has been very good, ~33% of treated patients have experience a recurrence of their lymphoma in the salivary/lacrimal glands, lymph nodes, or other sites. [20]
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 (5.4%) died. [4] [5] In the United States, 2.1% of people are affected at some point in their life. [2] The most common age of diagnosis is between 65 and 75 years old. [2] The five-year survival rate in the United States is 71%. [2]
The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 85%, [4] while that for non-Hodgkin lymphomas is 69%. [15] Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. [16] They make up 3–4% of all cancers, making them as a group the seventh-most-common form.
In childhood, T-cell acute lymphoblastic leukemia (T-ALL) patients can expect a 5-year event-free survival (EFS) rate of 70% and an overall survival (OS) rate of 80%. [1] Among the approximately 25% of children who relapse, survival rates drop to 30-50%, with patients generally showing a much poorer prognosis. [ 1 ]
The 14 year survival rates for patients with Lennert lymphoma, 56%, was significantly (p-value=003, Logrank test) greater than the 10% survival rate for patients with other types of peripheral T-cell lymphomas
Duodenal-type follicular lymphoma (DFL) is a form of lymphoma in which certain lymphocyte types, the B-cell-derived centrocytes and centroblasts, form lymph node follicle-like structures principally in the duodenum and other parts of the small intestine. It is an indolent disease which on rare occasions progresses to a more aggressive lymphoma ...
With treatment, typical survival with CUP ranges from 6 to 16 months. [7] Survival rates are lower in cases with visceral metastatic disease, ranging from 6 to 9 months. [7] Survival rates are higher when the cancer is more limited to lymph nodes, pleura, or peritoneal metastasis, which ranges from 14 to 16 months. [7]